Abstract
Cutaneous melanoma is the most aggressive skin cancer. Beside surgery, it is treated with chemotherapy and immunotherapy. However, many patients relapse after adjuvant therapy. The recent identification of several key molecular pathways implicated in the pathogenesis of melanoma is spreading development of a number of new translational targeted therapies which could play an important role in overcoming or minimizing resistance to chemotherapeutic drugs and proapoptotic therapies. This review summarizes environmental factors and the most significant molecular events involved in melanoma pathogenesis, disclosing mechanisms responsible for drug resistance and pointing out the clinical view for emerging targeted therapies. Standard therapies and an update on the current clinical trials are also described.
Keywords: Drug resistance, melanoma, BRAF, PI3K/AKT/mTOR, AF/MEK/ERK, sensitivity, targeted therapy, MEK, ERK, gene mutations
Current Drug Delivery
Title: Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Volume: 9 Issue: 1
Author(s): Francesca Maira, Alessia Catania, Saverio Candido, Alessia Erika Russo, James A. McCubrey, Massimo Libra, Grazia Malaponte and Concettina Fenga
Affiliation:
Keywords: Drug resistance, melanoma, BRAF, PI3K/AKT/mTOR, AF/MEK/ERK, sensitivity, targeted therapy, MEK, ERK, gene mutations
Abstract: Cutaneous melanoma is the most aggressive skin cancer. Beside surgery, it is treated with chemotherapy and immunotherapy. However, many patients relapse after adjuvant therapy. The recent identification of several key molecular pathways implicated in the pathogenesis of melanoma is spreading development of a number of new translational targeted therapies which could play an important role in overcoming or minimizing resistance to chemotherapeutic drugs and proapoptotic therapies. This review summarizes environmental factors and the most significant molecular events involved in melanoma pathogenesis, disclosing mechanisms responsible for drug resistance and pointing out the clinical view for emerging targeted therapies. Standard therapies and an update on the current clinical trials are also described.
Export Options
About this article
Cite this article as:
Maira Francesca, Catania Alessia, Candido Saverio, Erika Russo Alessia, A. McCubrey James, Libra Massimo, Malaponte Grazia and Fenga Concettina, Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs, Current Drug Delivery 2012; 9 (1) . https://dx.doi.org/10.2174/156720112798376032
DOI https://dx.doi.org/10.2174/156720112798376032 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Exosome-Based Drug Delivery for Regenerative Medicine
Exosome-based drug delivery is emerging as a transformative technology in regenerative medicine due to exosomes' natural ability to mediate intercellular communication and carry bioactive molecules like proteins, lipids, and nucleic acids. This thematic issue focuses on exosomes as nanocarriers for therapeutic delivery, harnessing their potential to enhance tissue repair, immune ...read more
Extracellular Vesicles as Drug Delivery Systems.
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design and Green Synthesis of Thieno[2,3-d]pyrimidine Analogues as Potential Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Synthetic Strategies for the Construction of δ-Carbolines: A Chemical Ladder in Search of Novel Drugs
Current Organic Synthesis Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets The Evaluation of Potential Cytotoxic Effect of Different Proton Pump Inhibitors on Different Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics
Current Pharmaceutical Design 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery
Current Pharmaceutical Design Steroid Receptor Ligands for Breast Cancer Targeting: An Insight into Their Potential Role As Pet Imaging Agents
Current Medicinal Chemistry TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Curcumin Inhibits Vasculogenic Mimicry <i>via</i> Regulating ETS-1 in Renal Cell Carcinoma
Current Cancer Drug Targets Therapeutic Enhancement of IL-2 Through Molecular Design
Current Pharmaceutical Design Re and Tc Complexes with Pyrazolyl-Containing Chelators: from Coordination Chemistry to Target-Specific Delivery of Radioactivity
Current Radiopharmaceuticals Molecular Mechanisms of Drug Photodegradation and Photosensitization
Current Pharmaceutical Design